Technetium Tc-99m medronate

Identification

Summary

Technetium Tc-99m medronate is a diagnostic radiopharmaceutical agent used as a bone imaging agent to delineate areas of altered osteogenesis.

Generic Name
Technetium Tc-99m medronate
DrugBank Accession Number
DB09138
Background

Technetium (99mTc) medronic acid is a pharmaceutical product used in nuclear medicine imaging. It is composed of a technetium ion complexed with medronic acid, a type of bisphosphonate. Like other bisphosphonates used in the treatment of osteoporosis, medronic acid binds to the hydroxyapatite crystals within bone, and in this way localizes the drug to bone for delineation of areas of altered osteogenesis. Following intravenous injection, single photon emission computed tomography (SPECT) is performed to detect the gamma ray emmitted by the decay of Technetium-99m to Technetium-99.

Type
Small Molecule
Groups
Approved
Structure
Thumb
Weight
Average: 305.906
Monoisotopic: 305.861006841
Chemical Formula
CH6O8P2Tc
Synonyms
  • 99m Tc medronate
  • 99m Tc-medronate
  • 99mTc medronate
  • 99mTc-medronate
  • AN-MDP
  • Cis-Mdp
  • Tc 99m Mdp
  • Tc-99m Mdp
  • Technetium (99mTc) medronic acid
  • Technetium (99mTc) Methylenediphosphonate
  • Technetium 99mTc medronic acid
  • Technetium methylene diphosphonate
  • Technetium Tc 99m medronate
  • Technetium Tc 99m medronic acid
  • Technetium Tc 99M Mpi Mdp

Pharmacology

Indication

Technetium Tc 99m Medronate is indicated for use as a bone imaging agent to delineate areas of altered osteogenesis.

Pharmacology
Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Associated Conditions
Contraindications & Blackbox Warnings
Contraindications
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

When injected intravenously, Technetium Tc 99m Medronate is rapidly cleared from the blood; about 50% of the dose is accumulated and retained by the skeleton, while the remaining 50% is excreted in the urine within 24 hours. About 10% of the injected dose remains in the blood at 1 hour post-injection, 5% at 2 hours, and less than 1% remains at 24 hours. Following intravenous administration of Technetium Tc 99m Medronate, skeletal uptake occurs as a function of blood flow to bone and bone efficiency in extracting the complex.

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Technetium Tc-99m decays by isomeric transition with a physical half-life of 6.02 hours.

Clearance

Not Available

Adverse Effects
Adverseeffects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
  • Drink plenty of fluids. Void urine as frequently as possible after the examination to minimize excess radiation of the bladder.

Products

Products2
Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Product Ingredients
IngredientUNIICASInChI Key
Technetium Tc-99m medronate disodiumV3V5VW82PO65871-22-9AXNBRPOESGBANA-KTTJZPQESA-F
Brand Name Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
Kit for the Preparation of Technetium Tc 99m MedronateInjection, powder, lyophilized, for solution20 mg/1IntravenousCardinal Health 414, Llc2020-12-01Not applicableUS flag
Kit for the Preparation of Technetium Tc 99M MedronateInjection, powder, lyophilized, for solution20 mg/10mLIntravenousSun Pharmaceutical Industries, Inc.1979-08-29Not applicableUS flag
MDP-BraccoInjection, powder, lyophilized, for solution20 mg/1IntravenousBracco Diagnostics, Inc1981-02-172015-05-31US flag

Categories

ATC Codes
V09BA02 — Technetium (99mtc) medronic acid
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as bisphosphonates. These are organic compounds containing two phosphonate groups linked together through a carbon atoms.
Kingdom
Organic compounds
Super Class
Organic acids and derivatives
Class
Organic phosphonic acids and derivatives
Sub Class
Bisphosphonates
Direct Parent
Bisphosphonates
Alternative Parents
Organic phosphonic acids / Organic transition metal salts / Organopnictogen compounds / Organophosphorus compounds / Organic oxides / Hydrocarbon derivatives
Substituents
Aliphatic acyclic compound / Bisphosphonate / Hydrocarbon derivative / Organic oxide / Organic oxygen compound / Organic salt / Organic transition metal salt / Organophosphonic acid / Organophosphorus compound / Organopnictogen compound
Molecular Framework
Not Available
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
X89XV46R07
CAS number
121524-79-6
InChI Key
IUPNVOAUFBLQME-SGNQUONSSA-J
InChI
InChI=1S/CH6O6P2.2H2O.Tc/c2-8(3,4)1-9(5,6)7;;;/h1H2,(H2,2,3,4)(H2,5,6,7);2*1H2;/q;;;+4/p-4/i;;;1+1
IUPAC Name
(⁹⁸Tc)technetium(4+) ion dihydrate (phosphonatomethyl)phosphonate
SMILES
O.O.[98Tc+4].[O-]P([O-])(=O)CP([O-])([O-])=O

References

General References
  1. Jiang RF, Zhang L, Cheng B, Huang Z, Li DL, Wang MM, Lu XT, Zhang YX, Cao W: Increased uptake of Tc-99m-methylene diphosphonate in the jaw. Clin Imaging. 2015 Nov-Dec;39(6):1068-72. doi: 10.1016/j.clinimag.2015.06.009. Epub 2015 Jul 16. [Article]
  2. Yang F, Yang Z, Feng J, Zhang L, Ma D, Yang J: Three phase bone scintigraphy with (99m)Tc-MDP and serological indices in detecting infection after internal fixation in malunion or nonunion traumatic fractures. Hell J Nucl Med. 2016 May-Aug;19(2):130-4. doi: 10.1967/s002449910366. Epub 2016 Jun 22. [Article]
  3. Ballani NS, Al-Huda FA, Khan HA, Al-Mohannadi S, Mahmood H, Al-Enezi F: The value of quantitative uptake of (99m)Tc-MDP and (99m)Tc-HMPAO white blood cells in detecting osteomyelitis in violated peripheral bones. J Nucl Med Technol. 2007 Jun;35(2):91-5. Epub 2007 May 11. [Article]
KEGG Drug
D02029
PubChem Compound
131704315
PubChem Substance
310265053
ChemSpider
34995234
RxNav
1488818
ChEBI
32186
ChEMBL
CHEMBL2110576
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Technetium_(99mTc)_medronic_acid
FDA label
Download (1.68 MB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4CompletedDiagnosticSkeletal injury1
2CompletedDiagnosticMalignancies1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
Injection, powder, lyophilized, for solutionIntravenous20 mg/10mL
Injection, powder, lyophilized, for solutionIntravenous20 mg/1
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility13.5 mg/mLALOGPS
logP1.03ALOGPS
logP-2.4ChemAxon
logS-1.5ALOGPS
pKa (Strongest Acidic)1.27ChemAxon
Physiological Charge-2ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area126.38 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity23.39 m3·mol-1ChemAxon
Polarizability10.06 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Drug created on September 30, 2015 16:19 / Updated on October 09, 2021 02:48